Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 12 June 2026 it repurchased 41,800 H shares on the Hong Kong Stock Exchange, spending HK$1.12 million. The shares were acquired within a price range of HK$26.00–27.70, giving a volume-weighted average cost of HK$26.8349 per share.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.031% to 134.92 million shares, while treasury holdings rose to 1.29 million shares. Total issued shares remained unchanged at 136.22 million.

The buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.29 million shares, representing 0.95% of the share count on the mandate date.

Under Hong Kong listing rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 July 2026. The board confirmed that the repurchase was conducted in full compliance with all applicable regulations.